Care este prețul pentru Novo Nordisk A/S (NOVO-B)

Prețul pentru Novo Nordisk A/S (NOVO-B) este $44.39

Care este capitalizarea de piață pentru Novo Nordisk A/S (NOVO-B)

Capitalizarea de piață pentru Novo Nordisk A/S (NOVO-B) este $197.21B

Novo Nordisk A/S (NOVO-B) Raport P/B

Novo Nordisk A/S operates as a global healthcare enterprise, dedicated to the innovation, development, production, and commercialization of pharmaceutical solutions. Its business is primarily divided into two key segments: Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity Care segment offers a comprehensive portfolio of treatments for diabetes (including insulins, GLP-1 analogues, oral antidiabetic agents, and related delivery systems), obesity management, glucagon, medical needles, and other chronic conditions. The Rare Disease segment provides specialized medications for haemophilia, various blood disorders, endocrine imbalances, growth hormone deficiencies, and hormone replacement therapy. Additionally, the company engages in strategic alliances, including a partnership with Gilead Sciences, Inc., and conducts research focused on identifying cell-specific carriers for nucleic acid-based therapies. Established in 1923, Novo Nordisk A/S is headquartered in Bagsvaerd, Denmark.

An	Raport P/B	Schimbă
Nu sunt suficiente date pentru perioada selectată.

Raport P/B

Schimbă

Nu sunt suficiente date pentru perioada selectată.

Companie	Raport P/B	Diferență raport P/B	Țara
Eli Lilly and Company LLY.US	29.9692	209.20%	US
Johnson & Johnson JNJ.US	7.6479	-21.09%	US
AbbVie Inc. ABBV.US	-78.0908	-905.68%	US
Roche Holding AG RO.SW	8.4776	-12.53%	CH
Merck & Co., Inc. MRK.US	8.5385	-11.91%	US

Companie

Raport P/B

Diferență raport P/B

Țara